Xi'an ruixi Biological Technology Co

Home > Keywords >

Catalog	name	Description	price
R-C-1252	Mdivi-1 CAS：338967-87-6	Mdivi-1 is a selective cell-permeable inhibitor of mitochondrial division dynamin-related GTPase(DRP1)and mitochondrial division dynamin I(Dnm1).Mdivi-1 inhibits apoptosis by inhibiting mitochondrial outer membrane permeabilization. Mdivi-1 is the first selective inhibitor of mitochondrial division dynamins. Mdivi-1 represents a class of therapeutics for stroke,myocardial infarction,and neurodegenerative diseases.	price>
R-R-2952	CFM 1571 hydrochloride CAS No.1215548-30-3	CFM 1571 hydrochloride/CAS No.1215548-30-3 is the stimulator of the nitric oxide receptor, soluble guanylate cyclase (sGC) with an EC50 and IC50 of 5.49 μM and 2.84 μM, respectively. Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric oxide (NO). CFM 1571 hydrochloride has the potential for the research of cardiovascular and other diseases.	price>
R-C-1253	Tubastatin A(free base) CAS：1252003-15-8	Tubastatin A is a potent and selective HDAC6 inhibitor. Tubastatin A demonstrates 1093-fold selectivity over HDAC1(IC50 values of 15 nM for HDAC6 vs 16.4 µM for HDAC1).Tubastatin A was substantially more selective than the known HDAC6 inhibitor Tubacin at all isozymes except HDAC8.	price>
R-R-2953	Dolcanatide CAS No.1092457-65-2	Dolcanatide/CAS No.1092457-65-2 is an orally active GC-C (guanylate cyclase-C) agonist. Dolcanatide shows laxative, anti-nociceptive and anti-inflammatory activity. Dolcanatide can be used in inflammatory bowel disease research.	price>
R-C-1254	CCT007093 CAS：176957-55-4	CCT007093 is an effective protein phosphatase 1D(PPM1D Wip1)inhibitor.Wip1 inhibition can activate the mTORC1 pathway and enhance hepatocyte proliferation after hepatectomy.	price>
R-R-2954	Guanylin(human) TFA	Guanylin(human) TFA, a 15-amino acid peptide, is an endogenous intestinal guanylate cyclase activator. Guanylin(human) TFA is mainly found in gastrointestinal tract which regulates electrolytead water transport in intestinal and renal epithelia through cyclic GMP-dependent mechanism.	price>
R-C-1255	Quisinostat CAS:875320-29-9	SB-3CT is a potent matrix metalloproteinase MMP-2 and MMP-9 inhibitor.SB-3CT is a 2-[(arylsulfonyl)methyl]thiirane that achieves potent inhibition,by a thiirane-opening mechanism,of the MMP2 and MMP9 zinc metalloproteases.SB-3CT attenuates behavioral impairments and hippocampal loss after traumatic brain injury in rat.Matrix metalloproteinases(MMPs)are involved in a number of activities including angiogenesis and embryogenesis.In particular,gelatinases A (MMP-2)and B(MMP-9),are thought to facilitate tumor metastasis.	price>
R-R-2955	Ebselen oxide CAS No.104473-83-8	Ebselen oxide/CAS No.104473-83-8, the selenone analogue of Ebselen, covalently modifies diguanylate cyclase (DGC) to inhibit c-di-GMP-receptor interactions and reduces DGC activity. Ebselen oxide also inhibits alginate production (IC50=14 μM) by Pseudomonas aeruginosa. Ebselen oxide inhibits HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9 (IC50 ranging from 0.2 to 4.7 μM).	price>
R-C-1256	Rimonabant CAS:168273-06-1	Rimonabant(SR141716)is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane.Rimonabant is also a dual inhibitor of acyl CoA:cholesterol acyltransferases(ACAT)1 and 2 and inhibits mycobacterial MmpL3.	price>
R-R-2956	Cysmethynil CAS No.851636-83-4	Cysmethynil/CAS No.851636-83-4 is an Icmt inhibitor(IC50 = 2.4 μM). Cysmethynil inhibites RAS membrane binding and EGF signal transduction. Cysmethynil prevents the cells in the G1 phase and induces autophagy. Cysmethynil inhibits PC3 cells proliferation, has synergistic effect with Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A). Cysmethynil has anti-tumor effects and can be used for solid tumor (such as prostate cancer et al.) research.	price>
R-C-1257	BIO CAS: 667463-62-9	BIO(GSK-3 Inhibitor IX,6-bromoindirubin-3-oxime,6-Bromoindirubin-3-oxime,MLS 2052)is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/βin a cell-free assay,shows>16-fold selectivity over CDK5,also a pan-JAK inhibitor with IC50 of 30 nM for Tyk2.BIO induces apoptosis in human melanoma cells.	price>
R-R-2957	N-Salicyloyltryptamine CAS No.31384-98-2	N-Salicyloyltryptamine/CAS No.31384-98-2 acts on voltage-dependent Na+, Ca2+, and K+ ion channels inhibitor. N-Salicyloyltryptamine inhibits K+ currents with an IC50 value of 34.6 μM (Ito). N-Salicyloyltryptamine also exhibits anticonvulsant, anti-inflammatory, analgesic, and vasorelaxation effect-.	price>
R-C-1258	ZLN005 CAS No. 49671-76-3	ZLN005 is a PGC-1α Transcriptional Regulator,which shoed some beneficialfEffects on diabetic db/db mice.ZLN005 increased fat oxidation and improved the glucose tolerance, pyruvate tolerance,and insulin sensitivity of diabetic db/db mice.Hyperglycemia and dyslipidemia also were ameliorated after treatment with ZLN005.	price>
R-R-2958	Sotorasib CAS No.2296729-00-3	Sotorasib (AMG-510)/CAS No.2296729-00-3 is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib is the first KRAS G12C inhibitor in clinical development and leads to the regression of KRAS G12C tumors.	price>
R-C-1259	MS436 CAS No. 1395084-25-9	MS436 is a BRD4 inhibitor.MS436,through a set of water-mediated interactions, exhibits low nanomolar affinity(estimated Ki of 30-50 nM).MS436 effectively inhibits BRD4 activity in NF-κB-directed production of nitric oxide and proinflammatory cytokine interleukin-6 in murine macrophages.	price>
R-R-2959	MRTX1133 CAS No.2621928-55-8	MRTX1133/CAS No.2621928-55-8 is a noncovalent, potent, and selective KRAS G12D inhibitor. MRTX1133 optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated KD against KRAS G12D of 0.2 pM. MRTX1133 prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRAS G12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells. MRTX1133 has single digit nanomolar activity in cellular assays and marked in vivo efficacy in tumor models harboring KRAS G12D mutations.	price>
R-C-1260	BRD4770 CAS：1374601-40-7	BRD4770 is a histone methyltransferase G9a inhibitor.BRD4770 reduces di- and trimethylation of lysine 9 on histone H3(H3K9)with an EC50 of 5 µM,and has less or little effect toward H3K27me3,H3K36me3,H3K4me3,and H3K79me3.BRD4770 can activate the ataxia telangiectasia mutated(ATM)pathway and induce cell senescence.	price>
R-R-2960	BI-2865 CAS No.2937327-93-8	BI-2865/CAS No.2937327-93-8 is a none-covalent pan-KRAS Inhibitor. BI-2865 binds to WT, G12C, G12D, G12V and G13D mutant KRAS with KDs of 6.9, 4.5, 32, 26, 4.3 nM respectively. BI-2865 inhibits the proliferation of G12C, G12D or G12V mutant KRAS expressing BaF3 cells (mean IC50: roughly 140 nM).	price>
R-C-1261	YL-109 CAS ： 36341-25-0	YL-109 has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo.YL-109 repressed the sphere-forming ability and the expression of stem cell markers in MDA-MB-231 mammosphere cultures.YL-109 increased the expression of carboxyl terminus of Hsp70-interacting protein(CHIP),which suppresses tumorigenic and metastatic potential of breast cancer cells by inhibiting the oncogenic pathway.YL-109 induced CHIP transcription because of the recruitment of the aryl hydrocarbon receptor(AhR)to upstream of CHIP gene in MDA-MB-231 cells.Consistently,the antitumor effects of YL-109 were depressed by CHIP or AhR knockdown in MDA-MB-231 cells.YL-109 inhibits cell growth and metastatic potential by inducing CHIP expression through AhR signaling and reduces cancer stem cell properties in MDA-MB-231 cells.	price>
R-R-2961	BI-2852 CAS No.2375482-51-0	BI-2852/CAS No.2375482-51-0 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based agent design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D versus KRASwt (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells.	price>

499500501502503504 505506507508509